Amee J. George
YOU?
Author Swipe
View article: 77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial
77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial Open
View article: Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia
Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia Open
Despite advances in therapy, specific subtypes Acute Myeloid Leukaemia (AML) remains largely incurable. The first-in-class RNA Polymerase I (Pol I) inhibitor, CX-5461, has demonstrated promising activity in both haematological malignancies…
View article: The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignancies
The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignancies Open
Ribosome biogenesis (RiBi) is a key determinant of cell growth and proliferation and is highly elevated in cancer due to the activation by oncogenes such as MYC . First-generation RiBi inhibitor CX-5461, while demonstrating clinical potent…
View article: Supplementary Methods, Tables S1 - S3, Figure Legends from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Methods, Tables S1 - S3, Figure Legends from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This document contains additional materials and methods details, tables of antibody and primer details and supplementary data figure legends.
View article: Supplementary Figure S1 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S1 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 1 including cell death, cell signalling and mRNA transcription analysis data.
View article: Supplementary Figure S2 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S2 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 2 including cell death and tumour cell analysis data.
View article: Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 3 including protein and cell immunofluorescence analysis data.
View article: Supplementary Figure S1 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S1 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 1 including cell death, cell signalling and mRNA transcription analysis data.
View article: Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 3 including protein and cell immunofluorescence analysis data.
View article: Data from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Data from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
Ribosome biogenesis and protein synthesis are dysregulated in many cancers, with those driven by the proto-oncogene c-MYC characterized by elevated Pol I–mediated ribosomal rDNA transcription and mTORC1/eIF4E-driven mRNA translation…
View article: Supplementary Figure S2 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S2 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 2 including cell death and tumour cell analysis data.
View article: Supplementary Methods, Tables S1 - S3, Figure Legends from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Methods, Tables S1 - S3, Figure Legends from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This document contains additional materials and methods details, tables of antibody and primer details and supplementary data figure legends.
View article: Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 4 including protein and cell death analysis data.
View article: Data from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Data from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
Ribosome biogenesis and protein synthesis are dysregulated in many cancers, with those driven by the proto-oncogene c-MYC characterized by elevated Pol I–mediated ribosomal rDNA transcription and mTORC1/eIF4E-driven mRNA translation…
View article: Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Open
This figure shows supplementary data pertinent to Figure 4 including protein and cell death analysis data.
View article: Cell death and barrier disruption by clinically used iodine concentrations
Cell death and barrier disruption by clinically used iodine concentrations Open
Povidone-iodine (PVP-I) inactivates a broad range of pathogens. Despite its widespread use over decades, the safety of PVP-I remains controversial. Its extended use in the current SARS-CoV-2 virus pandemic urges the need to clarify safety …
View article: Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway
Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway Open
The nucleolar surveillance pathway monitors nucleolar integrity and responds to nucleolar stress by mediating binding of ribosomal proteins to MDM2, resulting in p53 accumulation. Inappropriate pathway activation is implicated in the patho…
View article: Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells
Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells Open
SNAT2 (SLC38A2) is a sodium-dependent neutral amino acid transporter, which is important for the accumulation of amino acids as nutrients, the maintenance of cellular osmolarity, and the activation of mTORC1. It also provides net glutamine…
View article: Cohesin mutations are synthetic lethal with stimulation of WNT signaling
Cohesin mutations are synthetic lethal with stimulation of WNT signaling Open
Mutations in genes encoding subunits of the cohesin complex are common in several cancers, but may also expose druggable vulnerabilities. We generated isogenic MCF10A cell lines with deletion mutations of genes encoding cohesin subunits SM…
View article: Author response: Cohesin mutations are synthetic lethal with stimulation of WNT signaling
Author response: Cohesin mutations are synthetic lethal with stimulation of WNT signaling Open
Article Figures and data Abstract Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Mutations in genes encoding subunits of th…
View article: A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting
A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting Open
Estimates of seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have been hampered by inadequate assay sensitivity and specificity. Using an enzyme-linked immunosorbent assay–based approach that combi…
View article: A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting
A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting Open
Estimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate assay sensitivity and specificity. Using an ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor bi…
View article: Cohesin mutations are synthetic lethal with stimulation of WNT signaling
Cohesin mutations are synthetic lethal with stimulation of WNT signaling Open
Mutations in genes encoding subunits of the cohesin complex are common in several cancers, but may also expose druggable vulnerabilities. We generated isogenic MCF10A cell lines with deletion mutations of genes encoding cohesin subunits SM…
View article: MODULATION OF RNA POLYMERASE I TRANSCRIPTION IN NORMAL AND MALIGNANT HAEMATOPOIESIS
MODULATION OF RNA POLYMERASE I TRANSCRIPTION IN NORMAL AND MALIGNANT HAEMATOPOIESIS Open
View article: A functional genetic screen defines the AKT-induced senescence signaling network
A functional genetic screen defines the AKT-induced senescence signaling network Open
View article: A novel modifier gene of the p53-mediated nucleolar stress response activated by ribosomal protein depletion
A novel modifier gene of the p53-mediated nucleolar stress response activated by ribosomal protein depletion Open
Event Abstract Back to Event A novel modifier gene of the p53-mediated nucleolar stress response activated by ribosomal protein depletion Mei S. Wong1, 2, 3, Sheren J. Al-Obaidi1, 2, Katherine M. Hannan1, 2, 3, Nadine Hein1, 2, Kaylene J. …
View article: Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient
Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient Open
Diamond Blackfan Anemia (DBA) is a rare blood disorder characterized by red cell aplasia and is often accompanied by a variety of congenital abnormalities. It typically presents in infancy with macrocytic anemia and is associated with an i…
View article: Repurposing ARBs as treatments for breast cancer
Repurposing ARBs as treatments for breast cancer Open
An increased understanding of G-protein-coupled
\nreceptors (GPCRs) has greatly influenced modern
\nmedicine, where approximately 30 to 50% of all
\nmarketed drugs act by binding to GPCRs. The
\nangiotensin II receptor type 1 (AT1R), a cla…
View article: Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population Open
Key Points Inhibition of RNA Pol I by CX-5461 treats aggressive AML and outperforms standard chemotherapy regimens. CX-5461 induces p53-dependent apoptosis, p53-independent cell-cycle defects and differentiation, and reduces LICs.
View article: The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma Open
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs)…